Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2024 May;9(5):103005.
doi: 10.1016/j.esmoop.2024.103005. Epub 2024 Apr 30.

Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology

P Queirolo  1 , M Cinquini  2 , G Argenziano  3 , F Bassetto  4 , P Bossi  5 , A Boutros  6 , C Clemente  7 , V de Giorgi  8 , M Del Vecchio  9 , R Patuzzo  10 , E Pennachioli  1 , K Peris  11 , P Quaglino  12 , A Reali  13 , I Zalaudek  14 , F Spagnolo  15
Affiliations
Practice Guideline

Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology

P Queirolo et al. ESMO Open. 2024 May.

Abstract

Cutaneous squamous cell carcinoma (CSCC) accounts for ∼20%-25% of all skin tumors. Its precise incidence is often challenging to determine due to limited statistics and its incorporation with mucosal forms. While most cases have a favorable prognosis, challenges arise in patients presenting with locally advanced or metastatic forms, mainly appearing in immunocompromised patients, solid organ transplantation recipients, or those facing social difficulties. Traditionally, chemotherapy and targeted therapy were the mainstays for advanced cases, but recent approvals of immunotherapeutic agents like cemiplimab and pembrolizumab have revolutionized treatment options. These guidelines, developed by the Italian Association of Medical Oncologists (AIOM) using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach, aim to guide clinicians in diagnosing, treating, and monitoring patients with CSCC, covering key aspects from primitive tumors to advanced stages, selected by a panel of experts selected by AIOM and other national scientific societies. The incorporation of these guidelines into clinical practice is expected to enhance patient care and address the evolving landscape of CSCC management.

Keywords: CSCC; GRADE; anti-PD-1; cemiplimab; cutaneous squamous cell carcinoma; guidelines; keratinocyte carcinoma; skin cancer.

PubMed Disclaimer

Conflict of interest statement

Disclosure PQue reported consulting or advisory role for Roche/Genentech, Novartis, MSD, Bristol Myers Squibb, Pierre Fabre, Sanofi, Sun Pharma Advanced Research Company, Merck Serono; travel, accommodations, expenses from MSD Oncology, Sanofi/Regeneron. FB reported advisory role for SunPharma; speaker fee, travel/accommodations for presentations or lectures for Sanofi/Regeneron; honoraria as consultant for Roche, Novartis. PB reported consulting or advisory role for Merck, Sanofi, Merck Sharp & Dohme, Sun Pharma, Angelini, Molteni, Bristol-Myers Squibb, GSK; research funding by GSK, MSD, Sanofi, BMS. MDV reported consulting or advisory role for Novartis, MSD, Bristol Myers Squibb, Pierre Fabre, Immunocore. KP reported advisory board roles with Abbvie, LEO Pharma, Janssen, Almirall, Eli Lilly, Galderma, Novartis, Pierre Fabre, Sun Pharma, and Sanofi. PQua reported advisory board and speaker fee from Sanofi, SunPharma, IGEA. IZ reported advisory board and speaker fee from Sanofi, SunPharma, Philogen, Regeneron, Novartis, MSD, Cieffe Derma, La Roche Posay, BMS, Almirall. FS reported honoraria for presentations or lectures from Sanofi Genzyme, Roche, BMS, Novartis, Merk, Sun Pharma, MSD, Pierre Fabre; participation on advisory board for Novartis, Philogen SunPharma, and MSD. All other authors have declared no conflicts of interest.

References

    1. Green A.C., Olsen C.M. Cutaneous squamous cell carcinoma: an epidemiological review. Br J Dermatol. 2017;177:373–381. - PubMed
    1. AIOM and AIRTUM working group I numeri del cancro in Italia. https://www.aiom.it/wp-content/uploads/2018/10/2018_NumeriCancro-operato... Available at.
    1. Wilson A., Goltsman D., Nankervis J., Clark J., Gupta R., Ashford B. Defining the incidence of cutaneous squamous cell carcinoma in coastal NSW Australia. Australas J Dermatol. 2022;63:213–216. - PMC - PubMed
    1. Que S.K.T., Zwald F.O., Schmults C.D. Cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2018;78:237–247. - PubMed
    1. Karia P.S., Han J., Schmults C.D. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol. 2013;68:957–966. - PubMed

Publication types